Wednesday, 2 April 2025
26.8 C
Singapore
29 C
Thailand
20 C
Indonesia
26.6 C
Philippines

23andMe to lay off 40% of workforce amid cost-cutting drive

23andMe cuts 40% of its workforce, saving US$35M, to refocus on core services after a tough year with layoffs and a data breach.

In a significant restructuring move, genetic testing company 23andMe announced on Monday that it is reducing its workforce by 40%, affecting over 200 employees. This decision is part of a broader strategy to cut costs as the company re-focuses on its core genetic testing services and strategic research partnerships.

CEO outlines cost-cutting measures and strategic changes

23andMe’s CEO and co-founder Anne Wojcicki described the layoffs as a โ€œdifficult but necessaryโ€ step to secure the company’s long-term stability. The layoffs are expected to save 23andMe more than US$35 million, enabling it to streamline its operations while concentrating on its primary consumer products and research collaborations.

In a statement, Wojcicki expressed sympathy for the affected employees but noted the urgency of reducing costs. “These actions were not easy, but they are critical for our continued focus on what we do best: providing trusted genetic information to consumers and building valuable partnerships that advance research.”

Therapeutics programs set to close as company shifts focus

Alongside the layoffs, 23andMe confirmed plans to discontinue its therapeutics division, which has focused on drug development using data from its vast genetic database. The companyโ€™s therapeutics programs, which included two immuno-oncology initiatives, aimed to develop new cancer treatments by harnessing the bodyโ€™s immune system to target cancer cells. According to the therapeutics divisionโ€™s website, these programs were designed to โ€œrestore the ability of the bodyโ€™s immune cells to kill cancer cells.โ€

Despite years of investment, 23andMeโ€™s therapeutic ventures have faced challenges. While the companyโ€™s genetic data has been valuable in providing insights for personalised healthcare and genetic research, the shift away from drug development marks a strategic pivot. Shutting down these programs will allow 23andMe to dedicate its resources and expertise to the core areas of consumer genetic testing and research partnerships.

Challenges and setbacks in the past year

The restructuring follows a challenging year for 23andMe, which has faced both security and financial setbacks. In April of last year, the company became the target of a significant cybersecurity breach, which exposed the personal data of 6.9 million users. The breach reportedly went undetected for over 18 months, raising serious concerns about the companyโ€™s data protection practices.

Following the breach, 23andMe was subject to a US$30 million settlement in a class-action lawsuit, and the scandal led to the resignation of the entire board of directors. These events have pressured the company to improve its data security and rebuild its reputation with consumers, investors, and regulatory bodies.

This series of challenges has pushed 23andMe to re-evaluate its business model. By focusing on genetic testing and its associated research partnerships, 23andMe hopes to stabilise financially and continue offering its unique services to millions of customers. However, these significant layoffs and program closures indicate that the companyโ€™s journey to recovery may still face obstacles.

23andMe was founded in 2006, gaining a reputation for its affordable, at-home genetic testing kits that provide insights into ancestry and health predispositions. Over the years, it has expanded into medical research, working with pharmaceutical companies to leverage its extensive genetic database. Despite its successes in these areas, the company now seems intent on narrowing its focus to core services while reducing the scale of its operations.

The company has not yet detailed specific support measures for employees affected by the layoffs, though it has expressed commitment to assisting them during the transition. As the company scales back on its drug development ambitions, 23andMe’s primary focus will remain on consumer genetic insights and research-driven partnerships.

Hot this week

The Tesla Model Y now comes in a 110kW version that qualifies for Cat A COE

Tesla launches the Model Y 110 in Singapore, a budget-friendly EV with Cat A COE. Discover its features, price, and availability.

ESET uncovers RansomHub links to rival gangs and highlights emerging EDR killer threats

ESET uncovers RansomHubโ€™s links to rival gangs and reveals its custom EDR killer, signalling new threats in the ransomware landscape.

Sony unveils WF-C710N earbuds with improved battery life and noise cancellation

Sony announces the WF-C710N earbuds, which offer better battery life and noise cancellation, and new colours for the WH-CH720N and WH-CH520 headphones.

Intel remains on course for next-gen CPUs

Intel CEO Lip-Bu Tan confirms that next-gen CPUs, including Panther Lake and Nova Lake, remain on track, with Panther Lake arriving in 2025.

Nothing Phone (3a) Pro review: A mid-range marvel with standout zoom

Nothing Phone (3a) Pro blends standout design, powerful zoom camera, and smart features, making it a top choice in the mid-range segment.

These robot vacuums are getting smarter with Apple Home support

Appleโ€™s iOS 18.4 update adds Matter support for robot vacuums, enabling control via Apple Home. Roborock, iRobot, and Ecovacs are updating their devices.

Gmail introduces easier encryption for business emails

Google introduces a new encryption model for Gmail, making it easier for businesses to send secure emails without special software or certificates.

Nothing Phone (3a) Pro review: A mid-range marvel with standout zoom

Nothing Phone (3a) Pro blends standout design, powerful zoom camera, and smart features, making it a top choice in the mid-range segment.

Vivo challenges iPhone 16 Pro Max with X200 Ultraโ€™s video stability

Vivoโ€™s X200 Ultra teaser compares video stability with the iPhone 16 Pro Max, promising top-tier camera upgrades and advanced stabilisation.

Related Articles